Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL, all the13Dropouts from Chapel Hill have come to aid along with local pigeons trying to push it down to 10 before close today. Will the M&A guru survive the day? What a relief should they not borrow enough to short, but hey having mixed feelings cause I sure like those cheapies!! Oh well, all things false are eventually reamed out so that leronlimab can fill the void where it truly belongs serving the public good.
Amazing how CytoDyn has survived the attempted pigeon coop...coup, the recouperation from fda/nada/kareem et al. Such resilience I have not witnessed before in pharma. Well, there have been a few others who sued the fda and won, but did they also have the internal sabotage power struggle? They wanted Nada out but he proved to be a tough Iranian along with his bud from Amar soon to be AmarXXX. That mistake sure will come in handy in the form of millions. Take that along with partnerships mentioned by Jared, non-dilutive at that! MAYBE A MERGER too. Here's one that just took place in the OTC. https://www.streetwisereports.com/article/2024/06/26/copper-gold-co-s-both-rated-strong-buys-ahead-of-merger.html
Furthermore, the cat can be skinned in different ways. Just takes the will and the creative entrepreneur spirit just like Jared displays with CytoDyn.
https://www.kiplinger.com/investing/stocks/ipos/603076/spacs-101-what-is-a-spac-how-does-it-work
Yes Sir, of course, we are all familiar with the 13D SPAC that tried and failed to take over CytoDyn which I proudly fought against and help to succeed. Keeping Nada was better than the sell-out Chapel Tilt crew. We would not be here today had that been successful. So all is well that ends well. Very good job Team CytoDyn. All your hard work these last two years has paved a new sendero to proving up leronlimab. We commend you. $ASTA$ 2024
And of course there are reverse mergers.. most active sector of this has been in pharma stocks. !!!
Could be that some of the "interested parties" have this in mind? Who knows. Remains to be seen...but soon!!
Yea, Monday dupe, you are desperate and it’s ok, I know this board means a lot to you moron, buh bye
Moron- was July 1 the date? What day is July 1? Today or Monday?
Haha, so what, 1 more day for you
Um, check the ticker. Someone just dumped 2m shares and headed to $.12 any minute now
I´M BACK- We know. Every time Paulson needs to move some shares into the market, you show up.
Riddle me this--- Is Samsung going to sue CYDY into forced bankruptcy for the approx $44M owed?---
The Total Balance due as restructured under the Letter Agreement is $43,821,231.32.
https://www.sec.gov/Archives/edgar/data/1175680/000155837024004802/cydy-20240403x8k.htm
LERONLIMAB IS GOING TO BE A BLOCKBUSTER!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! IN THE ENTIRE OF WORLD!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!---
In the over 2 decades of leronsalines existence on this planet, please point to the data where this swill met its endpoints in a clinical study?
Didnt Lalezari and Cyrus both say they were going to publish some data? They both lied right? RIGHT?
Dont trump your way out of this by being evasive and ignorant, just answer the goddamn direct questions.
I´M BACK - LERONLIMAB IS GOING TO BE A BLOCKBUSTER!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! IN THE ENTIRE OF WORLD!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! GOOOOOOOOOOOOOOOOOOO LERONLIMAB GOOOOOOOOOOOOOOOOO CÝDY GOOOOOOOOOOOOOOOOOO AMERICA!!!!!!!!!!!!!!!!!!!!!!
GOOOOOOOOOOOOOOOOOOOO CYDY GOOOOOOOOOOOOOOOOOOOOOO AMERICA!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
CANCER, HIV-NASH AND MORE = LERONLIMAB = CYTODYN = AMERICA!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
YESSSSSSSSSSSSSSSSSS - 72 % SHORT = HUGE SHORT SQEEZE LIKE GAMESTOP VERY SOON!!!!!!!!!!!!?????????????
Thought so, keyboard warrior! Not to fret..:I have it already :)
Seems you read only what you want to…or you’d see many predictions from $2 down to current price, including the pump two weeks ago
Send me a PM and show yourself! Would love to chat
.10cents and bankruptcy your two claims to fame!!!
That’s correct. Senior management also. You have an MBA in something but I’m sure it did not produce any impact on your income.
Forty years? LOL
And you pump a scam stock that lost 95% of its value!
Bravo! Shows that time only counts when you’re in prison. Keep up the great work.
#makingdupesbrokeagain
You’re the dumb one moron. Spent 40 years in the healthcare world. What have you done except spend time on a stock board. Man you shorts are ignorant
There's a mute button stupid. Use it!
As long as you morons keep paying their salaries this will never go bankrupt. So congrats longs your zombie biotech is still here. LAUGHING
You're right, all drugs do go through that process, IN ACADEMIA not in a clinical stage biotech you moron!!! Clinical stage biotechs should be well past that nonsense and should be you know running clinical trials!! God you longs are dumb!!!
250,000 ask slap at 15 and still stuck there says todays PR has pump and dump written all over it.
When will you dumb dupes ever learn?
LAUGHING
Now watch Paul boyz read this post and let the ask price move up.
Upside down!
Here’s the actual post from nearly a month ago! Is the price $.14 today? Or did it run on news
Bahahaha
UpsideDown-
Bankruptcy hasn’t happened yet because insiders use shares to enrich themselves
They have no urgency. Now, go back and read the thread below. When this ran to $.40 a few weeks ago, I outlined EXACLTY what would happen
Now what happened? It ran back to $.12 and the next filing was JayJay begging for $.09 a share! I don’t mind being off on my timeline… but never insinuate that you’ve been right and I’ve been wrong!
This is a SCAM!! This company is trash and none of the nonsensical musings of bagholders will change that.
So go ahead and call out Grip all you want as you watch this turd swill around the toilet bowl!! That’s your reality
I’ll be back for the funeral! But ya never know, could drop like a stone any time!
Grip out
Absolutely not true and evidence you have no idea what you’re talking about. All drugs go through this process on a possible new indication. FDA requires this process and documentation
For a "clinical stage biotech" mouse studies are pathetic! No one is righting this ship they are just getting paid!
Just as you predicted.10 another prediction has been bankruptcy over and over which has NOT happened. Everything that has been posted by several on this forum has been negative. The fact the Dr Jay is righting the ship is made to be a negative by most on this forum. I was never a fan of Nader from day one and to be honest only invested in CytoDyn after doing scientific analysis of the drug. Due to tremendous mismanagement, the drug has been delayed in approval and still has many hurdles to surpass before breaking out. You can either believe it may happen or believe it may not. I am on the positive side that believes the drug will impact the lives of many positively. Good luck to you in your self inflicted silence.
Paulson grabbing his 13% vig and laughing to the bank while baggies get excited about Ratatouie and his mice buddies getting the shot!
Enjoy the $.14 on that great PR! I’ll honor my bet but will be back for the Chapter 11 announcement!
It will be soon because there is no money and no shares left. So dance around and play the fool while you celebrate at $.14 stock!
After tomorrow, Grip will pause and let you yap with all the other baggies. I trust there are other pragmatic folks in the board who will call out this scam!
All the best!
My question to the board is two fold.
1. Do you think Grip has left or is hedging as the Big Grass Hopper1? Would be a typical pigeon maneuver.
2. "..... in combination with Resmetirom, a drug recently approved by the FDA. The study will evaluate leronlimab’s potential role in preventing and/or reversing liver fibrosis." will end up as a full collaboration with/in combination with Resmetirom, a drug recently approved by the FDA along with breakthrough designation, fast track, and priority review. The study will evaluate leronlimab’s potential role in preventing and/or reversing liver fibrosis.The FDA granted the approval of Rezdiffra to Madrigal Pharmaceuticals.[2] Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis.[1] It is a thyroid hormone receptor beta (NR1A2) agonist.[1]
It does have side effects and some have to stop using it. A combo pill with leronlimab might just fit the bill. Watch it happen.The horses have left the starting gate. Good job CytoDyn Team. $CYDY$ 2024
CYDY´S MILLS GRIND!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
What, are you on something, did I say I wouldn’t honor the bet, if it touches .10 by Monday July 1, I will delete my account, Got it
CYDY...149...VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC Laboratories, Inc. (“SMC”) has commenced, with results expected in the fall of 2024.
CytoDyn believes its prior MASH study demonstrated a statistically significant benefit of leronlimab at a dosing level of 350 mg. To clarify the optimal dosing and evaluate the potential for combination therapy, SMC will be conducting a twelve-week preclinical mouse study evaluating both 350 and 700 mg dose levels, alone and in combination with Resmetirom, a drug recently approved by the FDA. The study will evaluate leronlimab’s potential role in preventing and/or reversing liver fibrosis.
CytoDyn’s CEO, Dr. Jacob Lalezari, stated, “in addition to clarifying dosing and efficacy, the goal of this study is to eventually use the results to pursue partnerships in the MASH space. Although CytoDyn will be primarily focused on oncology and inflammation in the coming months, we do believe that leronlimab could have a significant role in the treatment of MASH, whether as a standalone therapeutic or in a combination therapy approach.”
Meh- I might welch too! Just a matter of time. None of you have honor when you say you won’t honor the bet a week ago
Yup, and nothing you can do about it dupe, enjoy these last two days mullet head
To pump this garbage so insiders can make money on their $.09 warrants.
And the duped lap it up. They’re excited because it might not hit $.10 on our bet. Notwithstanding two of these mullets weighed already
Why would Cytodyn announce a pre-clinical study for MASH?
The FDA Has Approved a New Treatment for a Liver Disease Called MASH (Metabolic Dysfunction-Associated Steatohepatitis)
GOOOOOOOOOOOOOOOOOOO CYDY GOOOOOOOOOOOOOOOOOO AMERICA!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
YESSSSSSSSSSSSSSSSSSSSSSS - START OF PRECLINICAL MASH STUDY - RESULTS EXPECTED IN FALL 2024!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
WISH EVERYONE A GREAT BLESSED DAY AND CYDY A LOT OF GREEN DAYS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Good night mountanman5.
Leronlimab is great.
WISH EVERYONE A GREAT BLESSED NIGHT
You’re $.14 from bankruptcy Mohammed! Now show your predictions
What a clown
like your bankruptcy BS? lol..classic.
Knowing the chair of the board and you answer your own question.
Paulson has been receiving cashless warrants for years as part of the payment for brokering CYDY raises. They also take 13% of the cash raised. Very nice profit for Paulson.
My questions to board are. Is Paulsen getting cashless warrants?. If they are what is value of these warrants to paulsen?. It seems that if they are,this is very very bad for investors other than Paulsen. In fact ,it would seem that Paulsen is running board for their own profit. I challenge board members to address these questions.
This was probably you! Actually not because you’re broke but this would be a move you’d make! Buy High- Sell Low
12:08:38 100,000 Buy 0.1549
Already upside down! Bahaha
The S&P 500 trades at a cyclically adjusted (Shiller) P/E of 34 right now. That's in the top 1% most expensive at any time in history - only in 1929, 1972, Japan in 1989 and the Tech Bubble of 1999 has the market been this expensive. In every case, we had 10 years of dismal returns from those levels - because when you double the price, you halve the return. Simple math. Also, in every case, the market mean reverted to trend - which is about 3,200 on the S&P.
So, you may be right about a new bull market - but it would just buck every market trend in history if that occurred. And to those who think AI has changed the game, that's exactly what they were saying about the internet in 1999 to justify the crazy multiple back then (and i think we can all agree the internet was a pretty groundbreaking technology itself). Everyone wants to torture the logic at the top to justify that the party will continue.
For me, I'm preparing for a much more difficult backdrop going forward based on valuation. And as a side note, i've been short NVDA for a few weeks now to put my money where my mouth is (the hype reminds me of CSCO in 99' - which still hasn't recovered to it's high - 25 years later). The question for this board, is how will CytoDyn fare when the backdrop gets more challenging? I can't think it will be good for company that continually needs to raise new capital.
Followers
|
810
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
233243
|
Created
|
11/18/05
|
Type
|
Free
|
Moderators janice shell kgromax |
DISCLAIMER:
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn. The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity.
In addition, the Company and certain of its executives have received subpoenas in connection with an investigation being conducted by the United States Department of Justice. The subpoenas seek testimony and/or records concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn.
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security.
The Company is cooperating fully with these non-public, fact-finding investigations, and as of the date of this filing, the Company is unable to predict the ultimate outcome and cannot reasonably estimate the potential possible loss or range of loss, if any.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn. “We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA. We will provide an update when we have additional information.”
Up to 205,652,848 Shares of Common Stock
This prospectus supplement updates, amends and supplements the prospectus dated October 11, 2023, relating to our Registration Statement on Form S-1 (Registration No. 333-272815) (as supplemented or amended from time to time, the “Prospectus”). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to supplement the Prospectus with the following information:
The information in this prospectus supplement includes forward-looking statements relating to, among other things, future clinical trials and our business strategy. The reader is cautioned not to rely on these statements, which are based on our current expectations. Please see below for additional information about risks involving our securities.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference. The Prospectus, together with this prospectus supplement, relates to the resale of up to 74,903,789 shares of our common stock, par value $0.001 per share (the “common stock”), and 130,749,059 shares of our common stock underlying certain warrants (collectively, the “Shares”), by the selling stockholders identified in the Prospectus under “Selling Stockholders”.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024 the closing price of our common stock was $0.2575 per share.
Investing in our securities involves risk. You should carefully consider the risks that we have described under the section captioned “Risk Factors” in the Prospectus on page 8 and in Part II, Item 1A of the 2024 Second Quarter 10-Q before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 1, 2024.
November 3, 2023
November 2023 Letter to Shareholders
Dear Shareholders,
We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company.
Throughout our history, CytoDyn has made great strides in developing leronlimab from a single indication molecule into a platform molecule with the potential for multiple therapeutic indications. Through CytoDyn’s investment in clinical trials, we have generated valuable data demonstrating how leronlimab might be used in HIV, oncology, metabolic dysfunction-associated steatohepatitis (“MASH” formerly “NASH”), and metabolic dysfunction-associated steatotic liver disease (“MASLD”). We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval.
Fiscal year 2023 proved to be a very difficult year for CytoDyn. We had planned to be off clinical hold and back to conducting clinical trials by now. Unfortunately, to date, we have been delayed in our efforts to satisfy the FDA with our clinical hold submission(s). We have embarked on a more comprehensive effort to resolve the FDA’s lingering questions. These efforts include the Company’s hosting of a number of advisory board meetings with key opinion leaders (KOLs). Adding to our delay was the unanticipated medical leave taken by our then President, Dr. Arman creating additional delays in our subsequent resubmission.
However, these unforeseen circumstances provided the time needed to help us gain new insights and understanding of leronlimab in the current HIV treatment environment. Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, notwithstanding other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come.
The Company has taken necessary actions to position us for near-term and long-term success. During the last fiscal year, the Company implemented significant reductions to its workforce, cash burn rate, and operating expenses, in order to conserve our resources and devote them to critical corporate priorities. In addition to our work in HIV, we have worked with top experts to develop a MASH clinical trial protocol and identify potential MASH pre-clinical combination therapy trial concepts, which trials we believe could be attractive to a partner and position the Company for a greater chance of success within the MASH space. We also began development of a longer-acting therapeutic with a partner who has a very strong and reputable artificial intelligence (“AI”) platform, which we believe may provide significant increases in shareholder value in the years to come. We also believe that the Company is positioned for success in the Amarex litigation. We fully funded Sidley Austin LLP – the preeminent law firm representing the Company in this matter, filed a more-detailed statement of claim, and scheduled a final hearing date (August 12, 2024) in the arbitration.
We understand that CytoDyn’s recent challenges may have tested your confidence. We want to assure you that we remain dedicated to developing important therapeutics that can make a difference in
patients' lives, and at the same time provide value for our shareholders. Again, we are grateful for your ongoing support and trust.
We will continue our efforts to prioritize and execute on goals that will enhance value for all shareholders. Our efforts are focused on successfully completing the resolution of the FDA’s partial clinical hold – having recently made a submission that we hope will be successful – and strengthening our leadership team. Additionally, the Company will be evaluating the various potential indications for leronlimab to maximize the effective and efficient use of our resources. We have always believed leronlimab holds great promise, and we are determined to explore all avenues by which patients and medical practitioners can benefit from its use. We believe that with the improvements we have made and continue to pursue, our company is positioned for long-term success.
We deeply value your investment in CytoDyn and are committed to acting in your best interests. We look forward to continuing to communicate as additional developments occur. We realize the updates above may not answer all the questions you have. We therefore include a November 2023 “Frequently Asked Questions” supplement with this letter. This FAQ supplement is something we intend to update from time to time and it will be posted on the Company’s website in the near future.
Finally, in advance of our upcoming Annual Meeting on November 9, 2023, we want to remind you to submit your votes, if you have not already done so. If you were a shareholder as of September 11, 2023, you are considered a shareholder of record. Notably, the Company has asked for the shareholders’ approval to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock. This increased share allowance is critical to the ongoing viability of the Company, and we therefore encourage everyone to vote if you have not already done so. If you have any questions or require any assistance in voting your shares, please call the Company’s proxy solicitor, Alliance Advisors LLC, at (833) 814-9456.
Sincerely,
Tanya Durkee Urbach
Board Chair
Note Regarding Forward-Looking Statements
This letter and the accompanying Frequently Asked Questions supplement contain forward-looking statements relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and/or our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the Annual Report on Form 10-K for the fiscal year ended May 31, 2023, including in the sections captioned “Forward Looking Statements” and “Item 1A. Risk Factors”, as later supplemented by our Form 10-Q for the quarter ended August 31, 2023, in the section captioned “Item 1A. Risk Factors”. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |